Achieve Life Sciences
ACHV
33 hedge funds and large institutions have $14.6M invested in Achieve Life Sciences in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 2 closing their positions.
498% more call options, than puts
Call options by funds: $718K | Put options by funds: $120K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
14% more funds holding
Funds holding: 29 → 33 (+4)
0.12% more ownership
Funds ownership: 20.31% → 20.43% (+0.12%)
2% less capital invested
Capital invested by funds: $14.9M → $14.6M (-$296K)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
+$339K |
| 2 |
LPL Financial
San Diego,
California
|
+$131K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$97.7K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$90.4K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$76.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$362K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$148K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$143K |
| 4 |
Two Sigma Advisers
New York
|
-$35.5K |
| 5 |
SC
Shay Capital
New York
|
-$32.4K |
ACHV Hedge Fund Activity: Q1 2022 in Review
33 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q1 2022, worth a combined $14.6M — down 2% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ACHV positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was DLD Asset Management, opening a new position worth an estimated $339K. The largest seller was Morgan Stanley, cutting an estimated $362K.
- 33 institutional investors held Achieve Life Sciences (ACHV) as of Q1 2022, up from 29 in Q4 2021.
- Funds reported $14.6M of Achieve Life Sciences stock for Q1 2022, down 2% quarter-over-quarter.
- 6 funds opened new Achieve Life Sciences positions in Q1 2022 and 2 closed out, a net change of +4 holders.
- The largest Achieve Life Sciences buyer in Q1 2022 was DLD Asset Management, an estimated $339K added.
- The largest Achieve Life Sciences seller in Q1 2022 was Morgan Stanley, an estimated $362K sold.
Based on aggregated 13F filings for Q1 2022.